Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography
Cell & Gene Therapy Insights 2023; 9(4), 389–397
Cell and gene therapy vectors derived from lentivirus (LV) offer unique advantages over more conventional retroviral gene delivery systems. Considering the ability to integrate the host cell genome, LV vectors have become effective tools to transduce both dividing and non-dividing cells, thereby providing long-term stable gene expression. With a growing pipeline of LV particle-based therapies comes a prominent need for more efficient manufacturing processes that are meeting the demand of functional LVs required for clinical trials. Despite the manufacturing process improvements achieved over recent years, current unit operations are still unable to reverse the significant loss of biological LV particles during the downstream process. One of the major challenges has been the development of a truly selective affinity chromatography resin that can bind the viral envelope and simultaneously allow the preservation of its biological activity during elution. This article describes a new affinity resin, suitable for the purification of VSV-G pseudotyped lentivirus particles.